NRx Pharmaceuticals (NASDAQ:NRXP) PT Raised to $19.00

NRx Pharmaceuticals (NASDAQ:NRXP) had its price objective boosted by HC Wainwright from $2.00 to $19.00 in a report released on Monday morning, Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for NRx Pharmaceuticals’ Q2 2024 earnings at ($0.81) EPS, Q3 2024 earnings at ($0.81) EPS and Q4 2024 earnings at ($0.86) EPS.

Separately, Ascendiant Capital Markets dropped their target price on NRx Pharmaceuticals from $50.00 to $43.00 and set a buy rating on the stock in a report on Friday, June 7th.

NRx Pharmaceuticals Trading Up 5.6 %

NRx Pharmaceuticals stock opened at $2.06 on Monday. NRx Pharmaceuticals has a twelve month low of $1.90 and a twelve month high of $7.33. The stock’s fifty day simple moving average is $2.66 and its 200-day simple moving average is $18.60. The firm has a market capitalization of $22.04 million, a P/E ratio of -0.66 and a beta of 1.26.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its earnings results on Tuesday, May 14th. The company reported ($0.74) EPS for the quarter. Sell-side analysts predict that NRx Pharmaceuticals will post -4 earnings per share for the current year.

Hedge Funds Weigh In On NRx Pharmaceuticals

A hedge fund recently bought a new stake in NRx Pharmaceuticals stock. One Wealth Management Investment & Advisory Services LLC acquired a new stake in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 140,402 shares of the company’s stock, valued at approximately $65,000. One Wealth Management Investment & Advisory Services LLC owned approximately 0.16% of NRx Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.